Table 1.
Important characteristics of patients enrolled in the included studies
| Study, year | Study design | Sample size | Gender (M/F) | Age, years | Kellgren-Lawrence score (I:II:III:IV) | Clinical outcomes | Follow-up periods | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| PRP + HA | PRP | PRP + HA | PRP | PRP + HA | PRP | PRP + HA | PRP | ||||
| Zhao [19] | RCT | 62 | 62 | 35/27 | 37/25 | 55.73 ± 7.18 | 56.32 ± 8.13 | – | – | ① | 5 weeks |
| Rao [20] | RCT | 20 | 20 | – | – | 73.3 ± 7.2 | 73.3 ± 7.2 | – | – | ① | 5 weeks |
| Ke [21] | RCT | 50 | 50 | 25/25 | 24/26 | 57.80 ± 6.90 | 53.9 ± 7.1 | 5:11:20:14 | 6:12:20:12 | ②④⑤⑥ | 12 months |
| Ding [22] | RCT | 20 | 27 | 2/18 | 8/19 | 56.75 ± 9.536 | 62.11 ± 12.50 | 9:6:5:0 | 10:11:6:0 | ①②,⑤⑥ | 6 months |
| Yu [14] | RCT | 104 | 96 | 46/50 | 54/50 | 46.50 ± 7.50 | 46.20 ± 8.60 | – | – | ② | 12 months |
| Jacob [23] | RCT | 20 | 31 | – | – | – | – | – | – | ①/④ | 6 months |
| Sun [24] | RCT | 39 | 39 | 21/18 | 17/22 | 60.6 ± 8.4 | 58.4 ± 8.1 | 0:39:0:0 | 0:39:0:0 | ①②⑥ | 6 months |
| Lana [25] | RCT | 33 | 36 | 6/27 | 7/29 | 62 ± 6.1 | 60.9 ± 7 | 5:14:14:0 | 9:14:13:0 | ⑥ | 12 months |
| Xu [26] | RCT | 48 | 40 | – | – | 57.9 ± 4.1 | 56.9 ± 4.2 | 0:25:23 | 0:19:21 | ⑥ | 24 months |
| Huang [27] | Co, P | 31 | 33 | 8/23 | 8/25 | 63 ± 7.02 | 65.03 ± 7.10 | 0:10:10:11 | 0:9:15:9 | ③⑥ | 6 months |
| Guo [28] | Co, R | 63 | 63 | 45/18 | 51/12 | 61.2 ± 9.6 | 60.7 ± 10.1 | 17:28:18:0 | 15:31:17:0 | ①②⑥ | 12 months |
| Abate [29] | Co, R | 40 | 40 | 31/9 | 21/19 | 56.7 ± 11.2 | 60.90 ± 9.0 | 0:23:17:0 | 0:19:21:0 | ①③ | 6 months |
| Palco [30] | Co, R | 28 | 23 | 12/16 | 12/11 | 62.71 ± 7.88 | 54.04 ± 10.4 | 0:8:20:0 | 0:10:13:0 | ①③ | 12 months |
RCT randomized control trail, Co Cohort study, P prospective study, R retrospective study. PRP platelet-rich plasma, HA hyaluronic acid
① VAS scores, ② WOMAC total scores, ③ KOOS, ④ IKDC scores, ⑤ Lequesne index scores, ⑥ Adverse events